Addressing side effects from antipsychotic treatment in schizophrenia.

Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY, USA.
The Journal of Clinical Psychiatry (Impact Factor: 5.81). 02/2011; 72(2):e07. DOI: 10.4088/JCP.9101tx3c
Source: PubMed

ABSTRACT Antipsychotic treatment of schizophrenia is associated with an array of adverse events, many of which are difficult for patients to tolerate and promote nonadherence to treatment. Serious adverse events include extrapyramidal symptoms (EPS), hyperprolactinemia, weight gain leading to metabolic syndrome, sedation, cognitive deficits, and hypotension. Clinicians need to be aware of each antipsychotic's propensity to cause these adverse events as well as strategies for avoiding or minimizing the occurrence of adverse events.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: This study explores relevant outcomes with flexibly dosed paliperidone extended-release (ER) in a real-world design. Research design and methods: Patients were recruited from 23 countries. Adults with non-acute schizophrenia (n = 1812), previously unsuccessfully treated with other oral antipsychotics, were transitioned to paliperidone ER and prospectively treated for 6 months. Main outcome measures: Primary efficacy outcome for patients switching for the main reason of lack of efficacy was ≥ 20% improvement in Positive and Negative Syndrome Scale (PANSS) total scores. For patients switching for main reasons other than lack of efficacy, primary outcome was non-inferiority in efficacy compared with the previous medication. Results: Among the lack-of-efficacy group, 61% achieved a ≥ 20% improvement in PANSS total scores from baseline to endpoint. For switchers from other than the lack-of-efficacy group, efficacy maintenance after switching to paliperidone ER was confirmed. Clinically relevant and statistically significant symptomatic improvements occurred for each patient group based on main reason for switching. Conclusion: Paliperidone ER was well tolerated and associated with a meaningful clinical response in patients who switched from other oral antipsychotics, with insomnia and anxiety as most frequent side-effects.
    Expert Opinion on Pharmacotherapy 02/2014; DOI:10.1517/14656566.2014.884071 · 2.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Neurotensin (NT) is a neuropeptide that is closely associated with, and is thought to modulate, dopaminergic and other neurotransmitter systems involved in the pathophysiology of various mental disorders. This review outlines data implicating NT in the pathophysiology and management of major mental disorders such as schizophrenia, drug addiction, and autism. The data suggest that NT receptor analogs have the potential to be used as novel therapeutic agents acting through modulation of neurotransmitter systems dys-regulated in these disorders.
  • [Show abstract] [Hide abstract]
    ABSTRACT: It is known that newer antidepressants, such as the selective serotonin reuptake inhibitors (SSRIs), provide advantages in tolerability over antidepressants such as the tricyclics. However, even within the SSRI class, differences in efficacy or tolerability exist between the individual drugs. Among the three most widely prescribed SSRIs are paroxetine, sertraline, and escitalopram. Escitalopram is commonly referred to as an SSRI, but also has well-documented allosteric properties, and thus can be further classed as an allosteric serotonin reuptake inhibitor. All three antidepressants are efficacious compared with placebo, but there is evidence that escitalopram is more effective than a range of other antidepressants. There are no direct data to regard either paroxetine or sertraline as a superior antidepressant. Escitalopram is superior compared with paroxetine, which has a less favorable tolerability profile. Paroxetine is associated with cholinergic muscarinic antagonism and potent inhibition of CYP2D6, and sertraline has moderate drug interaction issues in comparison with escitalopram. Overall, as an allosteric serotonin reuptake inhibitor that is somewhat different from classical SSRIs, escitalopram is the first choice judged by combined efficacy and tolerability, and nonclinical data have offered possible mechanisms through which escitalopram could be more efficacious, based on its interaction with orthosteric and allosteric binding sites at the serotonin transporter.
    International clinical psychopharmacology 01/2014; 29(4). DOI:10.1097/YIC.0000000000000023 · 3.35 Impact Factor
    This article is viewable in ResearchGate's enriched format